EHA Expert Interview with Professor Zhihui Li: Safe and Effective Use of Luspatercept Post-Allo-HSCT in Patients with Hematologic Malignancies

EHA Expert Interview with Professor Zhihui Li: Safe and Effective Use of Luspatercept Post-Allo-HSCT in Patients with Hematologic Malignancies

The 29th Annual Meeting of the European Hematology Association (EHA) was held from June 13 to 16, 2024, in Madrid, Spain. As the largest international conference in the field of hematology in Europe, it attracts experts and scholars from around the world to share and discuss innovative ideas and the latest scientific and clinical research findings in hematology. At this year's conference, Professor Zhihui Li from Beijing GoBroad Boren Hospital presented research on the "Safety and Efficacy of Luspatercept in Allogeneic Transplantation for Malignant Hematologic Diseases." This study provides valuable insights for clinical practice. Oncology Frontier - Hematology Frontier had the opportunity to interview Dr. Zhihui Li at the conference to delve into the study's findings and their clinical implications.
EHA China’s Voice | Breakthrough Studies from Professor Huilai Zhang’s Team Unveiled at the EHA Annual Meeting – Deciphering the Genetic Secrets and New Treatment Strategies for Follicular Lymphoma

EHA China’s Voice | Breakthrough Studies from Professor Huilai Zhang’s Team Unveiled at the EHA Annual Meeting – Deciphering the Genetic Secrets and New Treatment Strategies for Follicular Lymphoma

The 29th European Hematology Association (EHA) Annual Meeting took place from June 13-16, 2024, in Madrid, Spain. At this prestigious event, Professor Huilai Zhang's team from Tianjin Medical University Cancer Institute and Hospital presented several research studies in poster sessions, highlighting the clinical features, genetic variations, and histological grading of follicular lymphoma. Their work offers a deeper understanding of the disease. Additionally, Professor Zhang's team delved into the epidemiological characteristics and prognosis of primary gastrointestinal follicular lymphoma, providing new insights for diagnosing and treating this rare disease. In the field of mantle cell lymphoma (MCL) treatment, their study on the Orelabrutinib-Lenalidomide-Rituximab regimen brings new hope to patients. Of particular note is their research on the impact of CD58 genetic alterations in diffuse large B-cell lymphoma (DLBCL), which enhances our understanding of the tumor immune microenvironment and suggests new approaches for personalized treatment. To provide a comprehensive overview of these research findings,Oncology Frontier - Hematology Frontier invited Professor Huilai Zhang to share the details.
Copy of Professor Jing Pan: Breakthroughs and Prospects of Performance-Enhanced CD33 CAR-T Cells in the Treatment of Relapsed or Refractory AML

Copy of Professor Jing Pan: Breakthroughs and Prospects of Performance-Enhanced CD33 CAR-T Cells in the Treatment of Relapsed or Refractory AML

In the field of hematologic oncology, treating acute myeloid leukemia (AML) has always been challenging, especially for relapsed or refractory patients. The limitations of traditional chemotherapy underscore the urgent need for innovative treatments. With advancements in immunotherapy, CAR-T cell therapy has introduced new breakthroughs in AML treatment. The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting was held from May 31 to June 4 in Chicago, USA. The "Phase I Study of Performance-Enhanced CD33 CAR-T Cells in Relapsed or Refractory AML Patients" was presented as a poster, aiming to explore the safety and preliminary efficacy of a novel CAR-T cell therapy in this patient group. "Oncology Frontier - Hematology Frontier " invited the study’s first author, Director Jing Pan from Beijing GoBroad Boren Hospital, to provide an in-depth interpretation of the research and share insights into advancements in AML diagnosis and treatment.
Welcome the Asia-Pacific AIDS & Co-Infections Conference (APACC) 2024

Welcome the Asia-Pacific AIDS & Co-Infections Conference (APACC) 2024

Over the years, enormous progress has been made in the fight against HIV and co-infections. Both academia and industry have contributed greatly to equipping the medical community with the best medications and expertise possible to optimally treat people living with HIV. However, international platforms for scientific interchange are not always accessible to medical professionals worldwide due to budget and travel restrictions. Also, most major conferences do not usually address local and regional issues. In particular, the Asian medical community in this field of research currently has very few platforms that serve the needs of HIV healthcare professionals in this region.
EASL Interview with Professor Arun J Sanyal: Breakthroughs in MAFLD Research and Discussion on the “Sugar-Liver Co-Management” Strategy

EASL Interview with Professor Arun J Sanyal: Breakthroughs in MAFLD Research and Discussion on the “Sugar-Liver Co-Management” Strategy

With the changing modern lifestyle and dietary patterns, Metabolic Associated Fatty Liver Disease (MAFLD) has gradually become one of the significant public health concerns globally. At the 2024 EASL Congress, there have been groundbreaking developments in the pharmacological treatment of MAFLD. Particularly, studies on the dual receptor agonists for Glucagon-Like Peptide-1 (GLP-1) and Glucose-Dependent Insulinotropic Polypeptide (GIP), survodutide, and tirzepatide, have revealed significant effects in alleviating hepatic steatosis and improving fibrosis. Additionally, due to its association with a range of cardiovascular diseases, diabetes, and other chronic metabolic disorders, the complex relationship between MAFLD and Type 2 Diabetes Mellitus (T2DM) has also garnered significant attention. Our journal had the privilege to interview Professor Arun J Sanyal, the Chair of the NASH Clinical Research Network at the National Institutes of Health, who summarized the latest clinical research progress on MAFLD from this conference and discussed the "Sugar-Liver Co-Management" strategy for patients with MAFLD and T2DM, aiming to provide new insights for clinical treatment and patient management.
Professor Man Li: TROP-2 ADC Combined with PD-1 Immunotherapy—SACI-IO HR+ Study Faces Challenges but Offers Valuable Insights| Man Talks Breast Cancer: ASCO Special

Professor Man Li: TROP-2 ADC Combined with PD-1 Immunotherapy—SACI-IO HR+ Study Faces Challenges but Offers Valuable Insights| Man Talks Breast Cancer: ASCO Special

In this "Man Talks Breast Cancer: ASCO Special," Professor Man Li's team from The Second Affiliated Hospital of Dalian Medical University has selected the latest ASCO studies on HR+ advanced breast cancer, covering topics such as cross-line treatment with CDK4/6 inhibitors, novel ADCs combined with ICIs, and comparing CDK4/6 inhibitors + ET with chemotherapy in premenopausal women. These can provide more valuable insights for clinical practice.
ASCO 2024丨Advances in Acute Myeloid Leukemia (AML) Treatment

ASCO 2024丨Advances in Acute Myeloid Leukemia (AML) Treatment

Acute myeloid leukemia (AML) is a highly heterogeneous hematologic malignancy, presenting significant challenges in treatment strategies and prognosis management for clinicians. At this year’s ASCO conference, several AML studies were presented. This article highlights three of them, covering the importance of frailty assessment, exploration of shortened treatment regimens, and interim results of new therapeutic agents. These advancements not only offer new insights into treatment strategies but also bring hope to patients.
Analysis of Clinical Characteristics and Prognostic Model Construction for Prostate Cancer Patients with a History of Malignancy by Professor Kan Gong ‘s Team | AUA 2024

Analysis of Clinical Characteristics and Prognostic Model Construction for Prostate Cancer Patients with a History of Malignancy by Professor Kan Gong ‘s Team | AUA 2024

With advancements in cancer screening, diagnosis, and treatment, the survival period of cancer patients has significantly increased. Long-term management of cancer patients should not only focus on the primary tumor but also monitor for the occurrence of secondary primary tumors (SPTs) and multiple primary tumors through regular check-ups and screenings. Secondary primary tumors are defined as new independent malignant tumors that arise in different locations following treatment for an initial malignancy, and they are not recurrences or metastases of the first primary tumor. Various factors may contribute to the development of SPTs, such as age, obesity, genetic susceptibility, the stage at diagnosis of the first primary tumor, and environmental exposure. Previous studies have shown that the incidence of SPTs in cancer patients ranges from 8-16%, varying by tumor site . SPTs pose a significant threat to cancer patients' survival, accounting for 55% of cancer-related deaths .
EHA Expert Commentary | Professor Bingcheng Liu: Establishment of a Prognostic Scoring System for Blast Phase Chronic Myeloid Leukemia – Insights from the European Leukemia Network Blast Phase Registry Study

EHA Expert Commentary | Professor Bingcheng Liu: Establishment of a Prognostic Scoring System for Blast Phase Chronic Myeloid Leukemia – Insights from the European Leukemia Network Blast Phase Registry Study

Chronic myeloid leukemia (CML) has a reliable prognostic scoring system during the chronic phase, but blast phase (BP) lacks comprehensive analysis of prognostic factors or standardized scoring systems. Despite the era of tyrosine kinase inhibitors (TKIs), outcomes for BP patients remain poor. From June 13 to 16, 2024, the 29th European Hematology Association (EHA) Annual Congress was held in Madrid, Spain. At the congress, based on data from CML-BP patients diagnosed across multiple countries, the European Leukemia Network established a prognostic scoring system for BP-CML, clearly stratifying CML-BP patients into three distinct survival groups. Hematology Frontier is honored to feature commentary from Professor Bingcheng Liu, Director of the Leukemia Diagnosis and Treatment Center at the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, on this study.
EHA 5-Minute Highlights丨Professor Zonghong Shao: Advances in New Drug Treatments for Myelodysplastic Syndromes (MDS)

EHA 5-Minute Highlights丨Professor Zonghong Shao: Advances in New Drug Treatments for Myelodysplastic Syndromes (MDS)

The treatment journey for Myelodysplastic Syndromes (MDS) is fraught with challenges due to its heterogeneity, hematopoietic failure, complications, and transformation risks, all of which significantly complicate therapy. Notably, the 29th Annual Meeting of the European Hematology Association (EHA 2024), held from June 13 to 16, 2024, showcased significant progress in the field of MDS treatment. In this issue of "Oncology Frontier - Hematology Frontier," we have invited Professor Zonghong Shao from Tianjin Medical University General Hospital to provide an in-depth introduction and commentary on key research in the MDS treatment domain. We hope Professor Shao's insightful sharing will reveal the latest developments in the MDS field, aiding our colleagues in grasping the forefront of treatment and jointly seeking better therapeutic options for MDS patients.